Gemcitabine Combined With Either Pemetrexed Or Paclitaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer

April 2010 in “ Lung cancer ”

Pasquale Comella, Vincenzo Emanuele Chiuri, Giuseppe De Cataldis, Gianfranco Filippelli, Luigi Maiorino, Giacomo Vessia, R Cioffi, S. Mancarella, Carlo Putzu, Ettore Greco, Laura Palmeri, Raffaele Costanzo, Antonio Avallone, Luca Franco

Studysummary This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on lungcancerjournal.info →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].

3 citations , October 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)”

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.

Innovative Sequence of Docetaxel–Gemcitabine Based on Preclinical Data in the Treatment of Advanced Non-Small Cell Lung Cancer: A Phase I Study

research Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study

3 citations , February 2005 in “Lung Cancer”

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

research First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

22 citations , November 2005 in “BMC Cancer”

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

Gemcitabine in Combination with Vinorelbine in Elderly Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer

research Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

9 citations , February 2012 in “Cancer Chemotherapy and Pharmacology”

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

research Clinical Value Analysis of Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer

June 2023 in “Deleted Journal”

In this study, combining pemetrexed with cisplatin in non-small cell lung cancer patients improved immune function and had lower blood toxicity compared to cisplatin with gemcitabine, despite similar disease control rates and other side effects between the two treatment groups.